Search - tctmd.com

Displaying 301 - 320 of 648

Sort: Relevancy | Date

Presentation TCT 2016

Spectrum and Assessment of TAVR Accessory Devices (Valvuloplasty Balloons, Neuroprotection Systems, and More)

Presenter: Nicole Ibrahim, Martin B. Leon

November 01, 2016

Presentation TCT 2016

Valve Degeneration and Mobility Considerations: Assessing Clinical Relevance

Presenter: Nicole Ibrahim, Martin B. Leon, Raj Makkar

November 01, 2016

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Debate: Is PCI Standard of Care in Left Main Disease After EXCEL and NOBLE? No - So Many Questions Are Still Unanswered!

Presenter: Robert A. Guyton, Martin B. Leon, Marc Ruel

October 31, 2016

Presentation TCT 2016

Debate: Is PCI Standard of Care in Left Main Disease After EXCEL and NOBLE? Yes the Issue Is No Longer in Doubt!

Presenter: Robert A. Guyton, Martin B. Leon, David E. Kandzari

October 31, 2016

Presentation TCT 2016

EFS in the USA: Challenges and Developments (An Investigators Perspective)

Presenter: Andrew Farb, Aaron V. Kaplan, Martin B. Leon

October 31, 2016

Presentation TCT 2016

Dedicated Stents for Specific Scenarios: Historical Perspectives and Stuttering Progress

Presenter: Chaim S. Lotan, Giora Weisz, Martin B. Leon

October 31, 2016

Presentation TCT 2016

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Evald H. Christiansen

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

Presentation TVT 2016

Newcomers and Important Design Concepts: TAVR in the Future

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Setting the Stage: An Overview of Design Characteristics in Current (and Future) TAVR Systems

Presenter: Martin B. Leon

June 16, 2016

Advertisement

Spectrum and Assessment of TAVR Accessory Devices (Valvuloplasty Balloons, Neuroprotection Systems, and More)

Valve Degeneration and Mobility Considerations: Assessing Clinical Relevance

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Debate: Is PCI Standard of Care in Left Main Disease After EXCEL and NOBLE? No - So Many Questions Are Still Unanswered!

Debate: Is PCI Standard of Care in Left Main Disease After EXCEL and NOBLE? Yes the Issue Is No Longer in Doubt!

EFS in the USA: Challenges and Developments (An Investigators Perspective)

Dedicated Stents for Specific Scenarios: Historical Perspectives and Stuttering Progress

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

What TAVR Needs Next . . . and What It’s Getting

Newcomers and Important Design Concepts: TAVR in the Future

Study Design for the PARTNER 3 Low-Risk Trial

Setting the Stage: An Overview of Design Characteristics in Current (and Future) TAVR Systems

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content